These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 30888566)

  • 21. Multiple values of
    Li Y; Zhou Y; Wang Q
    Clin Rheumatol; 2017 Oct; 36(10):2297-2305. PubMed ID: 28831580
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Marked increase in serum KL-6 and surfactant protein D levels during the first 4 weeks after treatment predicts poor prognosis in patients with active interstitial pneumonia associated with polymyositis/dermatomyositis.
    Arai S; Kurasawa K; Maezawa R; Owada T; Okada H; Fukuda T
    Mod Rheumatol; 2013 Sep; 23(5):872-83. PubMed ID: 22983659
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Performance of Candidate Serum Biomarkers for Systemic Sclerosis-Associated Interstitial Lung Disease.
    Elhai M; Hoffmann-Vold AM; Avouac J; Pezet S; Cauvet A; Leblond A; Fretheim H; Garen T; Kuwana M; Molberg Ø; Allanore Y
    Arthritis Rheumatol; 2019 Jun; 71(6):972-982. PubMed ID: 30624031
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Diagnostic Value of Krebs von den Lungen (KL-6) for Interstitial Lung Disease: A European Prospective Cohort.
    Millan-Billi P; Castellví I; Martinez-Martinez L; Mariscal A; Barril S; D'Alessandro M; Franquet T; Castillo D
    Arch Bronconeumol; 2024 Jun; 60(6):350-355. PubMed ID: 38644152
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serum level of KL-6 as a marker of interstitial lung disease in patients with juvenile systemic sclerosis.
    Veselý R; Vargová V; Ravelli A; Massa M; Oleksák E; D'Alterio R; Martini A; De Benedetti F
    J Rheumatol; 2004 Apr; 31(4):795-800. PubMed ID: 15088311
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical Utility of YKL-40 in Polymyositis/dermatomyositis-associated Interstitial Lung Disease.
    Hozumi H; Fujisawa T; Enomoto N; Nakashima R; Enomoto Y; Suzuki Y; Kono M; Karayama M; Furuhashi K; Murakami A; Inui N; Nakamura Y; Mimori T; Suda T
    J Rheumatol; 2017 Sep; 44(9):1394-1401. PubMed ID: 28711881
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serum Krebs von den Lungen-6 concentrations reflect severity of anti-melanoma differentiation-associated protein 5 antibody positive dermatomyositis associated interstitial lung disease.
    Zhu Y; Wang L; Sun Y; Wang J; Lv C; You H; Xu L; Wang F; Zhang M; Tan W; Ke Y
    Clin Exp Rheumatol; 2022 Feb; 40(2):292-297. PubMed ID: 34874831
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The value of serum Krebs von den lungen-6 as a diagnostic marker in connective tissue disease associated with interstitial lung disease.
    Ma H; Lu J; Song Y; Wang H; Yin S
    BMC Pulm Med; 2020 Jan; 20(1):6. PubMed ID: 31915006
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sequential changes of KL-6 in sera of patients with interstitial pneumonia associated with polymyositis/dermatomyositis.
    Bandoh S; Fujita J; Ohtsuki Y; Ueda Y; Hojo S; Tokuda M; Dobashi H; Kurata N; Yoshinouchi T; Kohno N; Takahara J
    Ann Rheum Dis; 2000 Apr; 59(4):257-62. PubMed ID: 10733471
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predicting factors of interstitial lung disease in dermatomyositis and polymyositis.
    Chen YJ; Wu CY; Shen JL
    Acta Derm Venereol; 2007; 87(1):33-8. PubMed ID: 17225013
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serum Krebs von den Lungen-6 level predicts disease progression in interstitial lung disease.
    Ko UW; Cho EJ; Oh HB; Koo HJ; Do KH; Song JW
    PLoS One; 2020; 15(12):e0244114. PubMed ID: 33332430
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical Characteristics and Risk Factors of Polymyositis and Dermatomyositis Combined with Interstitial Lung Disease in Patients Residing in the Northeast Sichuan Province of China.
    Li T; Tang ZY; Zhang QB; Xiao FN; Jian GL; Xie Y; Guo JW; Qing YF
    Curr Rheumatol Rev; 2023; 19(4):455-462. PubMed ID: 37005523
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CA15-3 and cancer associated serum antigen assays are alternatives to the KL-6 assay for measuring serum MUC-1 levels in patients with interstitial lung disease associated with polymyositis/dermatomyositis.
    Wong RC; Klingberg S; Wilson R
    J Rheumatol; 2002 Sep; 29(9):2021-2; author reply 2022. PubMed ID: 12233905
    [No Abstract]   [Full Text] [Related]  

  • 34. Krebs von den Lungen-6 associated with chest high-resolution CT score in evaluation severity of patients with interstitial lung disease.
    Qin H; Xu XP; Zou J; Zhao XJ; Wu HW; Zha QF; Chen S; Kang Y; Jiang HD
    Pulmonology; 2019; 25(3):143-148. PubMed ID: 30007895
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interstitial lung disease in polymyositis and dermatomyositis: longitudinal evaluation by pulmonary function and radiology.
    Fathi M; Vikgren J; Boijsen M; Tylen U; Jorfeldt L; Tornling G; Lundberg IE
    Arthritis Rheum; 2008 May; 59(5):677-85. PubMed ID: 18438901
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The predictive prognostic factors for polymyositis/dermatomyositis-associated interstitial lung disease.
    Sugiyama Y; Yoshimi R; Tamura M; Takeno M; Kunishita Y; Kishimoto D; Yoshioka Y; Kobayashi K; Takase-Minegishi K; Watanabe T; Hamada N; Nagai H; Tsuchida N; Soejima Y; Nakano H; Kamiyama R; Uehara T; Kirino Y; Sekiguchi A; Ihata A; Ohno S; Nagaoka S; Nakajima H
    Arthritis Res Ther; 2018 Jan; 20(1):7. PubMed ID: 29325580
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Risk Prediction Modeling Based on a Combination of Initial Serum Biomarker Levels in Polymyositis/Dermatomyositis-Associated Interstitial Lung Disease.
    Gono T; Masui K; Nishina N; Kawaguchi Y; Kawakami A; Ikeda K; Kirino Y; Sugiyama Y; Tanino Y; Nunokawa T; Kaneko Y; Sato S; Asakawa K; Ukichi T; Kaieda S; Naniwa T; Okano Y; Kuwana M;
    Arthritis Rheumatol; 2021 Apr; 73(4):677-686. PubMed ID: 33118321
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serum Krebs von den Lungen-6 level as a diagnostic biomarker for interstitial lung disease in Chinese patients.
    Hu Y; Wang LS; Jin YP; Du SS; Du YK; He X; Weng D; Zhou Y; Li QH; Shen L; Zhang F; Su YL; Sun XL; Ding JJ; Zhang WH; Cai HR; Dai HP; Dai JH; Li HP
    Clin Respir J; 2017 May; 11(3):337-345. PubMed ID: 26077281
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical Heterogeneity of Interstitial Lung Disease in Polymyositis and Dermatomyositis Patients With or Without Specific Autoantibodies.
    Chen F; Li S; Wang T; Shi J; Wang G
    Am J Med Sci; 2018 Jan; 355(1):48-53. PubMed ID: 29289262
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serum levels of Krebs von den Lungen-6 as a promising marker for predicting occurrence and deterioration of systemic sclerosis-associated interstitial lung disease from a Chinese cohort.
    Cao XY; Hu SS; Xu D; Li MT; Wang Q; Hou Y; Zeng XF
    Int J Rheum Dis; 2019 Jan; 22(1):108-115. PubMed ID: 30592376
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.